CoChat

Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy

Jing, Ying, Zhang, Yongchang, Wang, Jing, Li, Kunyan, Chen, Xue, Heng, Jianfu, Gao, Qian, Ye, Youqiong, Zhang, Zhao, Liu, Yaoming, Lou, Yanyan, Lin, Steven H, Diao, Lixia, Liu, Hong, Chen, Xiang, Mills, Gordon B, Han, Leng · 2021 · JNCI: Journal of the National Cancer Institute
Cited by 105

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Background: Accumulated evidence supports the existence of sex-associated differences in immune systems. Understanding the role of sex in immune-related adverse events (irAEs) is important for management of irAE in patients receiving immunotherapy. Methods: We performed meta-analysis on published clinical study data and multivariable logistic regression on pharmacovigilance data and applied a propensity algorithm to The Cancer Genome Atlas omics data. We further validated our observations in 2 independent in-house cohorts of 179 and 767 cancer patients treated with immune checkpoint inhibitors. Results: A meta-analysis using 13 clinical studies that reported on 1096 female patients (36.8%, 95% confidence interval [CI] = 35.0% to 38.5%) and 1886 male patients (63.2%, 95% CI = 61.5% to 65.0%) demonstrated no statistically significant irAE risk difference between the sexes (odds ratio [OR] = 1.19, 95% CI = 0.91 to 1.54, 2-sided P = .21). Multivariable logistic regression analysis of 12 225 patients from the Food and drug administration Adverse Event Reporting System (FAERS) and 10 979 patients from VigiBase showed no statistically significant difference in irAEs by sex. A propensity score algorithm used on multi-omics data for 6019 patients from The Cancer Genome Atlas found no statistically significant difference by sex for irAE-related factors or pathways. The retrospective analysis of 2 in-house patient cohorts validated these results (OR = 1.55, 95% CI = 0.98 to 2.47, false discovery rate = 0.13, for cohort 1; OR = 1.16, 95% CI = 0.86 to 1.57, false discovery rate = 0.39, for cohort 2). Conclusions: We observed minimal sex-associated differences in irAEs among cancer patients who received immune checkpoint inhibitor therapy. It may be unnecessary to consider sex effects for irAE management in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djab035

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 105

Metadata

Authors
Jing, Y., Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., Lou, Y., Lin, S. H., Diao, L., Liu, H., Chen, X., Mills, G. B., & Han, L.
Venue
JNCI: Journal of the National Cancer Institute
Published
2021-03-11
Volume
113
Issue
10
Pages
1396-1404
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W3134648386
Cited by
105
References
31
FWCI
5.95
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. https://app.cochat.ai/papers/10.1093/jnci/djab035
The paper
Jing, Y., Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., Lou, Y., Lin, S. H., Diao, L., Liu, H., Chen, X., Mills, G. B., & Han, L. (2021). Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djab035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.